CBS 2019
CBSMD教育中心
English

科学研究

科研文章

荐读文献

Clinical impact of PCSK9 inhibitor on stabilization and regression of lipid-rich coronary plaques: a near-infrared spectroscopy study Impact of post-intervention minimal stent area on 9-month follow-up patency of paclitaxel-eluting stents: an integrated intravascular ultrasound analysis from the TAXUS IV, V, and VI and TAXUS ATLAS Workhorse, Long Lesion, and Direct Stent Trials Considerations for Optimal Device Selection in Transcatheter Aortic Valve Replacement: A Review Primary Prevention Trial Designs Using Coronary Imaging: A National Heart, Lung, and Blood Institute Workshop Percutaneous Coronary Intervention for Vulnerable Coronary Atherosclerotic Plaque Clinical impact of conduction disturbances in transcatheter aortic valve replacement recipients: a systematic review and meta-analysis Why and How to Measure Aortic Valve Calcification in Patients With Aortic Stenosis Association of Reduced Apical Untwisting With Incident HF in Asymptomatic Patients With HF Risk Factors Intracoronary stenting without anticoagulation accomplished with intravascular ultrasound guidance Contribution of stent underexpansion to recurrence after sirolimus-eluting stent implantation for in-stent restenosis
|<<... 106 107 108 109 110 111 112 ...>>|

Original Research2018 Nov 15;92(6):E416-E424.

JOURNAL：Catheter Cardiovasc Interv. Article Link

Long-term outcomes after treatment of bare-metal stent restenosis with paclitaxel-coated balloon catheters or everolimus-eluting stents: 3-year follow-up of the TIS clinical study

Pleva L, Kukla P, Zapletalova J et al. Keywords: everolimus-eluting stent; in-stent restenosis; paclitaxel-eluting balloon

ABSTRACT



BACKGROUND - The efficacy of paclitaxel-eluting balloon catheters (PEB) and drug-eluting stents for treatment of bare-metal stent restenosis (BMS-ISR) have been demonstrated in several studies with follow-up times of 9 to 12 months; however, the long-term outcomes of ISR treatment are less defined.


OBJECTIVES - We aimed to compare the long-term efficacy of PEB and everolimus-eluting stents (EES) for the treatment of BMS-ISR.


METHODS - We analyzed 3-year clinical follow-up data from patients included in the TIS randomized clinical study. A total of 136 patients with BMS-ISR were allocated to receive treatment with either PEB or EES (68 patients with 74 ISR lesions per group).


RESULTS - The PEB and EES groups did not significantly differ in major adverse cardiac events-free survival (MACE; P = .211; including individual events: CV death: P = .622; myocardial infarction: P = .650 or target vessel revascularization: P = .286) at 3-year clinical follow-up. No event-free survival differences were found between the groups regarding overall mortality (P = .818), definite stent thrombosis (P = .165) or the second MACE (P = .270).


CONCLUSIONS - At the 3-year follow-up, no significant differences in clinical outcomes were found between iopromide-coated PEB and EES for the treatment of BMS-ISR. (ClinicalTrials.gov; https://clinicaltrials.gov; NCT01735825).

© 2018 Wiley Periodicals, Inc.


>CBS CBS 2019

> CBS 2019

> CBS 2019 注册

> CBS 2019 会议日程

> CBS 2019 学术征集

> CBS 2019 热点

 CBSMD

> CBSMD 网站注册

> 教育中心

> 荐读文献

> Top 10 阅读文献

> 文献导读
CBS 2019 CBS 2019 主席团 教育中心 科研动态
Copyright ⓒ CBS MD Nanjing China. All rights reserved. 京ICP备16025898号-11
联系我们| Top